RCKT

Rocket Pharmaceuticals, Inc. NASDAQ

Healthcare ·Biotechnology ·US · rocketpharma.com

$3.54

Mkt Cap $386.3M

52w Low $2.19 24.2% of range 52w High $7.77

50d MA $4.11 200d MA $3.55

P/E (TTM) -1.8x

EV/EBITDA -1.6x

P/B 1.4x

Debt/Equity 0.1x

ROE -80.5%

P/FCF -2.0x

RSI (14) —

ATR (14) —

Beta 0.57

50d MA $4.11

200d MA $3.55

Avg Volume 3.4M

About

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; le…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-0.42	-0.38	+9.5%	4.53	+1.3%	+10.6%	+9.7%	+6.0%	+6.4%	+2.4%	—
Nov 6, 2025	AMC	-0.48	-0.45	+6.2%	3.23	+0.9%	-1.9%	-2.5%	+0.9%	+2.2%	-1.9%	—
Aug 7, 2025	AMC	-0.57	-0.59	-3.5%	3.09	+1.0%	-7.4%	-5.5%	-5.8%	+0.0%	-1.9%	—
May 8, 2025	AMC	-0.59	-0.56	+5.1%	7.04	-0.4%	-0.7%	-0.6%	-6.0%	-13.9%	-4.4%	—
Feb 27, 2025	AMC	-0.68	-0.62	+8.8%	9.40	+1.6%	+0.5%	-6.5%	-7.9%	-2.0%	-4.4%	—
Nov 7, 2024	AMC	-0.78	-0.71	+9.0%	17.25	+0.2%	+1.2%	-2.3%	-7.1%	-9.2%	-14.1%	—
Aug 5, 2024	AMC	-0.74	-0.74	+0.0%	19.96	+4.5%	+0.9%	-5.3%	-4.2%	-4.6%	-5.1%	—
May 6, 2024	AMC	-0.69	-0.66	+4.3%	23.20	+0.8%	+0.7%	-0.9%	+0.6%	-2.1%	-0.5%	—
Feb 26, 2024	AMC	-0.80	-0.64	+20.0%	29.79	+5.0%	+3.2%	-2.6%	-1.6%	+2.5%	-3.6%	—
Nov 6, 2023	AMC	-0.82	-0.75	+8.5%	19.93	+1.6%	+2.7%	-1.8%	-8.8%	-6.9%	-2.1%	—
Aug 10, 2023	AMC	-0.80	-0.82	-2.5%	16.78	-1.2%	-1.5%	-0.4%	-3.2%	-6.0%	-8.6%	—
May 4, 2023	AMC	-0.86	-0.73	+15.1%	18.69	+1.7%	+12.4%	+14.3%	+10.6%	+12.0%	+8.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 30	BofA Securities	Maintains	Buy → Buy	—	$3.77	$3.75	-0.5%	-8.5%	-5.0%	-4.0%	-5.8%	-8.2%
Mar 27	Chardan Capital	Maintains	Buy → Buy	—	$4.69	$4.71	+0.4%	-19.6%	-26.4%	-23.7%	-22.8%	-24.3%
Mar 2	Goldman Sachs	Maintains	Sell → Sell	—	$5.01	$4.95	-1.2%	-0.8%	-4.2%	-3.8%	-7.4%	-12.0%
Feb 27	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.53	$4.59	+1.3%	+10.6%	+9.7%	+6.0%	+6.4%	+2.4%
Nov 18	BofA Securities	Maintains	Buy → Buy	—	$3.04	$2.90	-4.6%	-3.3%	-5.3%	-6.6%	-3.6%	-0.3%
Nov 18	JP Morgan	Downgrade	Overweight → Underweight	—	$3.04	$2.90	-4.6%	-3.3%	-5.3%	-6.6%	-3.6%	-0.3%
Oct 14	Chardan Capital	Maintains	Buy → Buy	—	$3.47	$3.92	+13.0%	+23.1%	+22.2%	+15.3%	+6.9%	+15.3%
Oct 3	Leerink Partners	Maintains	Market Perform → Market Perform	—	$3.21	$3.19	-0.6%	-1.9%	-0.9%	-2.2%	+5.6%	+14.3%
Aug 20	BofA Securities	Upgrade	Neutral → Buy	—	$2.91	$3.83	+31.6%	+28.9%	+28.2%	+25.1%	+21.6%	+16.5%
Aug 20	Chardan Capital	Maintains	Buy → Buy	—	$2.91	$3.83	+31.6%	+28.9%	+28.2%	+25.1%	+21.6%	+16.5%
Aug 11	Chardan Capital	Maintains	Buy → Buy	—	$2.86	$2.90	+1.4%	+2.1%	+1.7%	+8.0%	+5.9%	+6.6%
Aug 8	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$3.09	$3.12	+1.0%	-7.4%	-5.5%	-5.8%	+0.0%	-1.9%
Jul 25	BofA Securities	Downgrade	Buy → Neutral	—	$3.21	$3.11	-3.1%	-2.2%	-3.1%	-6.2%	-2.2%	-5.0%
Jul 25	Canaccord Genuity	Maintains	Buy → Buy	—	$3.21	$3.11	-3.1%	-2.2%	-3.1%	-6.2%	-2.2%	-5.0%
Jul 24	Needham	Maintains	Hold → Hold	—	$3.36	$3.32	-1.2%	-4.5%	-6.5%	-7.4%	-10.4%	-6.5%
Jul 24	Chardan Capital	Maintains	Buy → Buy	—	$3.36	$3.32	-1.2%	-4.5%	-6.5%	-7.4%	-10.4%	-6.5%
Jun 17	UBS	Maintains	Buy → Buy	—	$2.88	$2.87	-0.3%	-5.6%	-1.7%	-6.2%	-8.7%	-3.8%
Jun 3	Canaccord Genuity	Maintains	Buy → Buy	—	$2.77	$2.76	-0.4%	+6.9%	+5.4%	+0.0%	+10.8%	+9.0%
May 28	BMO Capital	Maintains	Outperform → Outperform	—	$2.33	$2.38	+2.1%	+6.4%	+12.4%	+7.7%	+18.9%	+27.0%
May 28	BofA Securities	Maintains	Buy → Buy	—	$2.33	$2.38	+2.1%	+6.4%	+12.4%	+7.7%	+18.9%	+27.0%
May 28	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$2.33	$2.38	+2.1%	+6.4%	+12.4%	+7.7%	+18.9%	+27.0%
May 28	Leerink Partners	Downgrade	Outperform → Market Perform	—	$2.33	$2.38	+2.1%	+6.4%	+12.4%	+7.7%	+18.9%	+27.0%
May 28	JP Morgan	Downgrade	Overweight → Neutral	—	$2.33	$2.38	+2.1%	+6.4%	+12.4%	+7.7%	+18.9%	+27.0%
May 28	Jefferies	Downgrade	Buy → Hold	—	$2.33	$2.38	+2.1%	+6.4%	+12.4%	+7.7%	+18.9%	+27.0%
May 28	Chardan Capital	Maintains	Buy → Buy	—	$2.33	$2.38	+2.1%	+6.4%	+12.4%	+7.7%	+18.9%	+27.0%
May 27	BofA Securities	Maintains	Buy → Buy	—	$6.27	$2.30	-63.3%	-62.8%	-60.4%	-58.2%	-60.0%	-55.8%
May 27	Needham	Downgrade	Buy → Hold	—	$6.27	$2.30	-63.3%	-62.8%	-60.4%	-58.2%	-60.0%	-55.8%
May 16	Wedbush	Maintains	Outperform → Outperform	—	$6.73	$6.87	+2.1%	-3.4%	-4.2%	+1.8%	-2.1%	-2.5%
May 16	Chardan Capital	Maintains	Buy → Buy	—	$6.73	$6.87	+2.1%	-3.4%	-4.2%	+1.8%	-2.1%	-2.5%
May 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.73	$6.87	+2.1%	-3.4%	-4.2%	+1.8%	-2.1%	-2.5%
May 12	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$6.99	$7.25	+3.7%	+0.1%	-5.3%	-13.3%	-3.7%	-7.0%
May 12	Canaccord Genuity	Maintains	Buy → Buy	—	$6.99	$7.25	+3.7%	+0.1%	-5.3%	-13.3%	-3.7%	-7.0%
May 9	JP Morgan	Maintains	Overweight → Overweight	—	$7.04	$7.01	-0.4%	-0.7%	-0.6%	-6.0%	-13.9%	-4.4%
May 9	Chardan Capital	Maintains	Buy → Buy	—	$7.04	$7.01	-0.4%	-0.7%	-0.6%	-6.0%	-13.9%	-4.4%
May 9	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.04	$7.01	-0.4%	-0.7%	-0.6%	-6.0%	-13.9%	-4.4%
Apr 9	Needham	Maintains	Buy → Buy	—	$4.79	$4.61	-3.8%	+12.7%	+3.1%	+10.0%	+23.4%	+36.3%
Mar 3	Canaccord Genuity	Maintains	Buy → Buy	—	$9.45	$9.42	-0.3%	-7.0%	-8.4%	-2.5%	-4.9%	-7.2%
Mar 3	Scotiabank	Maintains	Sector Outperform → Sector Outperform	—	$9.45	$9.42	-0.3%	-7.0%	-8.4%	-2.5%	-4.9%	-7.2%
Mar 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$9.45	$9.42	-0.3%	-7.0%	-8.4%	-2.5%	-4.9%	-7.2%
Feb 28	Needham	Maintains	Buy → Buy	—	$9.40	$9.55	+1.6%	+0.5%	-6.5%	-7.9%	-2.0%	-4.4%
Feb 28	Chardan Capital	Maintains	Buy → Buy	—	$9.40	$9.55	+1.6%	+0.5%	-6.5%	-7.9%	-2.0%	-4.4%
Feb 28	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$9.40	$9.55	+1.6%	+0.5%	-6.5%	-7.9%	-2.0%	-4.4%
Nov 19	Needham	Maintains	Buy → Buy	—	$13.66	$13.81	+1.1%	-3.7%	-4.5%	-6.4%	+3.3%	+3.2%
Nov 19	Leerink Partners	Maintains	Outperform → Outperform	—	$13.66	$13.81	+1.1%	-3.7%	-4.5%	-6.4%	+3.3%	+3.2%
Nov 19	Canaccord Genuity	Maintains	Buy → Buy	—	$13.66	$13.81	+1.1%	-3.7%	-4.5%	-6.4%	+3.3%	+3.2%
Nov 19	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$13.66	$13.81	+1.1%	-3.7%	-4.5%	-6.4%	+3.3%	+3.2%
Nov 18	Chardan Capital	Maintains	Buy → Buy	—	$13.98	$14.10	+0.9%	-2.3%	-5.9%	-6.7%	-8.5%	+0.9%
Nov 11	Chardan Capital	Maintains	Buy → Buy	—	$17.45	$17.65	+1.1%	-3.4%	-8.1%	-10.2%	-15.1%	-19.9%
Nov 8	Needham	Maintains	Buy → Buy	—	$17.25	$17.29	+0.2%	+1.2%	-2.3%	-7.1%	-9.2%	-14.1%
Sep 30	Canaccord Genuity	Maintains	Buy → Buy	—	$18.46	$18.22	-1.3%	+0.1%	-7.3%	-8.1%	-13.0%	-11.1%

Recent Filings

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

Rocket Pharmaceuticals disclosed material information via press release, likely regarding clinical trial results or pipeline updates that could significantly impact stock valuation and investor expectations for the biotech company's future performance.

Mar 27

8-K · 1.01 ! Medium

Unknown — 8-K 1.01: Equity Issuance

Rocket (RCKT) agreed to issue equity to Cantor Fitzgerald, likely diluting existing shareholders but providing capital for growth or debt reduction.

Mar 10

8-K

Rocket Pharmaceuticals, Inc. -- 8-K Filing

Rocket Pharmaceuticals reported 2025 results highlighting progress in its genetic therapy pipeline, particularly in cardiovascular applications with ongoing Danon disease experience and advancement in two additional cardiomyopathy programs.

Feb 26

Data updated apr 26, 2026 10:04pm · Source: massive.com